GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tryptamine Therapeutics Ltd (OTCPK:TYPTF) » Definitions » Other Stockholders Equity

TYPTF (Tryptamine Therapeutics) Other Stockholders Equity : $-0.00 Mil (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Tryptamine Therapeutics Other Stockholders Equity?

Tryptamine Therapeutics's Other Stockholders Equity for the quarter that ended in Dec. 2024 was $-0.00 Mil.

Tryptamine Therapeutics's quarterly Other Stockholders Equity declined from Jun. 2023 ($0.00 Mil) to Dec. 2023 ($-0.00 Mil) and declined from Dec. 2023 ($-0.00 Mil) to Dec. 2024 ($-0.00 Mil).

Tryptamine Therapeutics's annual Other Stockholders Equity increased from Jun. 2021 ($0.00 Mil) to Jun. 2022 ($0.00 Mil) but then declined from Jun. 2022 ($0.00 Mil) to Jun. 2023 ($0.00 Mil).

Tryptamine Therapeutics Other Stockholders Equity Historical Data

The historical data trend for Tryptamine Therapeutics's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tryptamine Therapeutics Other Stockholders Equity Chart

Tryptamine Therapeutics Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Other Stockholders Equity
Get a 7-Day Free Trial - - - - -

Tryptamine Therapeutics Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Dec24
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Tryptamine Therapeutics Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

Tryptamine Therapeutics Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Tryptamine Therapeutics's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Tryptamine Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tryptamine Therapeutics Ltd (OTCPK:TYPTF) » Definitions » Other Stockholders Equity
Comparable Companies
ASX:SPL ASX:CYP ASX:ADO ASX:RAD ASX:PTX ASX:ATX ASX:ATH ASX:ILA ASX:NUZ ASX:NOX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
TYP:Australia
Address
C/o Bio101 Financial Advisory Pty Ltd, 697 Burke Road, Suite 201, Camberwell, Melbourne, VIC, AUS, 3124
Website
https://www.tryptherapeutics.com
Tryptamine Therapeutics Ltd is a clinical-stage biotechnology company focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. The programs are designed to address neuropsychiatric disorders through the therapeutic dosing of synthetic psilocybin and IV infused psilocin in conjunction with psychotherapy. Its product pipeline includes TRP-8803 (IV-infused psilocin) and TRP-8802 (oral psilocybin).

Tryptamine Therapeutics Headlines

From GuruFocus

Exopharm Gains US Patent Enabling Commercial Production of Exosome Medicines

By PRNewswire PRNewswire • 12-22-2021

Exopharm and Astellas Institute for Regenerative Medicine (AIRM) Sign Master Collaborative Services Agreement

By PRNewswire PRNewswire • 01-31-2022